Checkpoint Therapeutics Stock
Your prediction
Pros and Cons of Checkpoint Therapeutics in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Cons
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Checkpoint Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics | - | - | - | - | - | - | - |
| Evolus Inc | -2.840% | -3.871% | -15.000% | -34.208% | -7.046% | -44.330% | -42.757% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.931% | -70.432% | -61.329% | -70.694% | -95.846% |
| Rhythm Pharmaceuticals | -6.560% | -5.000% | -11.856% | 14.765% | -8.556% | 437.736% | 493.750% |
Comments
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $9.00 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat